DCPrime was a spin-off of the Free University of Amsterdam, incorporated in 2005. The company developed an allogeneic dendritic cell line into cell therapeutic cancer treatments. As of December 21, 2020, DCprime completed the merger with Immunicum AB, to form a leader in the field of allogeneic dendritic cell biology. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm.